@ciriustx.com
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Cirius Therapeutics is a clinical-stage pharmaceutical company specializing in the development of innovative therapies for liver and metabolic diseases. Their primary focus is on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), common liver conditions often associated with type 2 diabetes. Cirius has developed a groundbreaking treatment called MSDC-0602K.
This oral small molecule medication is taken once daily and acts by selectively modulating the mitochondrial pyruvate carrier (MPC), which plays a crucial role in how the body processes nutrients and affects liver health. Phase 2b clinical trials of MSDC-0602K have shown its ability to deliver the beneficial effects of insulin sensitizers without the side effects caused by direct activation of PPAR nuclear receptors. Cirius is now preparing for Phase 3 studies, focusing on patients with NAFLD/NASH and type 2 diabetes.
With a talented board of directors, experienced management, and a dedicated scientific advisory board, Cirius Therapeutics is at the forefront of developing transformative treatments for metabolic disorders
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories